Results 131 to 140 of about 66,826 (280)

Surgical Reconstruction in Pyoderma Gangrenosum, a Retrospective Study of Five Patients

JEADV Clinical Practice, EarlyView.
ABSTRACT Pyoderma Gangrenosum (PG) is a neutrophilic dermatosis characterized by chronic painful ulcerations most commonly on the lower extremities. Current treatment options for PG are largely nonsurgical and include the use of systemic and topical immunomodulators and wound care.
Max E. Oscherwitz, Alysia B. Kohrs, Jacob C. Maus, Matthew L. Hrin, Maria C. Mariencheck, Joseph L. Jorizzo, Kyle E. Robinson, Joseph A. Molnar, Lindsay C. Strowd   +8 more
wiley   +1 more source

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Surgical Procedures and Medical Treatments Among Patients With Hidradenitis Suppurativa Before and After Referral to Specialised Dermatological Hospital Care: A Nationwide Registry Study

JEADV Clinical Practice, EarlyView.
Hidradenitis suppurativa (HS) is often diagnosed late, complicating management. In this nationwide Danish study including 10,196 patients with dermatologist‐verified HS, we examined treatment patterns before and after referral to specialised hospital care.
Nana A. L. Rosenø, Nadja Højgaard Pedersen, Yvonne Geissbühler, Nikolaj Holgersen, Valdemar Wendelboe Nielsen, Jacob P. Thyssen, Alexander Egeberg, Hans Christian Ring, Simon Francis Thomsen   +8 more
wiley   +1 more source

Management of Crohn's disease in poor responders to adalimumab

Clinical and Experimental Gastroenterology, 2014
Nanne KH de Boer,1 Mark Löwenberg,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the ...
de Boer NKH, Löwenberg M, Hoentjen F   +2 more
doaj  

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core  

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Acrodermatitis continua of Hallopeau: clinical perspectives. [PDF]

, 2019
Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of one or more digits. The condition presents with tender pustules and underlying erythema on the tip of a digit, more frequently arising on a finger than a toe.
Beck, Kristen M, Bhutani, Tina, Liao, Wilson, Ly, Karen, Smith, Mary Patricia, Thibodeaux, Quinn   +5 more
core  

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source